Ching-Fei Li
Impact in
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Immunology top 10%
- Galectins and Cancer Biology
- T-cell and B-cell Immunology
- Immune cells in cancer
- Immunotherapy and Immune Responses
Papers in
- Oncology 7
- Pancreatic and Hepatic Oncology Research 3
- Cancer Immunotherapy and Biomarkers 2
- Cancer Cells and Metastasis 1
- PARP inhibition in cancer therapy 1
-
- Galectins and Cancer Biology 3
- Co-authors
- Ri‐Yao Yang (3 shared papers)Mien‐Chie Hung (3 shared papers)Linlin Sun (2 shared papers)Hui Li (1 shared paper)Jong‐Ho Cha (1 shared paper)Jun Yao (1 shared paper)Jennifer L. Hsu (1 shared paper)Wei‐Chao Chang (1 shared paper)
- Journals
- Nature Communications (3 papers)Journal of Biological Chemistry (1 paper)Oncotarget (1 paper)Nature Cancer (1 paper)Cancer Research (1 paper)
- Partner nations
- United StatesTaiwanChina
In The Last Decade
Ching-Fei Li
9 papers receiving 706 citations
Ching-Fei Li's Hit Papers
Peers
Comparison fields: 5 of 60
- Oncology 304
- Immunology 202
- Cancer Research 46
- Genetics 25
- Immunology and Allergy 13
Countries citing papers authored by Ching-Fei Li
This map shows the geographic impact of Ching-Fei Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ching-Fei Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ching-Fei Li more than expected).
Fields of papers citing papers by Ching-Fei Li
This network shows the impact of papers produced by Ching-Fei Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ching-Fei Li. The network helps show where Ching-Fei Li may publish in the future.
Co-authors
The 25 scholars most cited alongside Ching-Fei Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy Hit paper breakdown → | 2021 | 492 |
| 2 | 2019 | 121 | |
| 3 | 2022 | 34 | |
| 4 | 2022 | 28 | |
| 5 | Erratum: The stabilization of PD-L1 by the endoplasmic reticulum stress protein GRP78 in triple-negative breast cancer. | 2020 | 19 |
| 6 | 2017 | 13 | |
| 7 | 2025 | 4 | |
| 8 | 2024 | 1 | |
| 9 | 2025 | 1 | |
| 10 | 2026 | 0 | |
| 11 | 2026 | 0 |
About Ching-Fei Li
Ching-Fei Li is a scholar working on Oncology, Immunology, Cell Biology, Molecular Biology and Surgery, having authored 11 papers that have together received 713 indexed citations. Recurring topics across this work include Galectins and Cancer Biology (3 papers), Pancreatic and Hepatic Oncology Research (3 papers), Epigenetics and DNA Methylation (2 papers), Cancer Immunotherapy and Biomarkers (2 papers), Cancer Cells and Metastasis (1 paper), Endoplasmic Reticulum Stress and Disease (1 paper), Bladder and Urothelial Cancer Treatments (1 paper) and PARP inhibition in cancer therapy (1 paper). The work is most often cited by research in Oncology (304 citations), Immunology (202 citations), Cancer Research (46 citations), Genetics (25 citations) and Immunology and Allergy (13 citations). Ching-Fei Li has collaborated with scholars based in United States, Taiwan and China. Frequent co-authors include Ri‐Yao Yang, Mien‐Chie Hung, Linlin Sun, Hui Li, Jong‐Ho Cha, Jun Yao, Jennifer L. Hsu, Wei‐Chao Chang, Chao‐Kai Chou and Meisi Yan. Their work appears in journals such as Nature Communications, Journal of Biological Chemistry, Oncotarget, Nature Cancer and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.